Company: AAOI
Filing Date: 2025-02-28
Form Type: 424B5
Source: 0001104659-25-019109
Chunk: 0

Company: APPLIED OPTOELECTRONICS, INC.
Filing Date: 2025-02-28
Form: 424B5
Chunk 0
---
TABLE OF CONTENTS

#### Filed pursuant to Rule 424(b)(5)​

#### Registration No. 333-283905​
**PROSPECTUS SUPPLEMENT 
 (To Prospectus dated December 18, 2024)**

<div align='center'>**$100,000,000**</div>

#### Applied Optoelectronics, Inc.

#### Common Stock
**We have entered into an Equity Distribution Agreement with Raymond James & Associates, Inc. (“Raymond James”), or the sales agreement, relating to shares of our common stock offered by this prospectus supplement. In accordance with the terms of the sales agreement, we may offer and sell through this prospectus supplement shares of our common stock having an aggregate offering price of up to $100,000,000 from time to time through Raymond James, acting as agent.

Our common stock is listed on The Nasdaq Global Market under the symbol “AAOI.” On February 25, 2025, the last reported sale price of our common stock on The Nasdaq Global Market was $23.34 per share.

Sales of our common stock, if any, under this prospectus supplement may be made in sales deemed to be “at-the-market” equity offerings as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, or the Securities Act, including sales made directly on or through The Nasdaq Global Market, the existing trading market for our common stock, sales made to or through a market maker other than on an exchange or otherwise, in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices, and any other method permitted by law, including in privately negotiated transactions. Raymond James is not required to sell any specific number or dollar amount of securities, but will act as sales agent and use commercially reasonable efforts to sell on our behalf all of the shares of common stock requested to be sold by us, consistent with its normal trading and sales practices, on mutually agreed terms between Raymond James and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.

Except as otherwise described in the sales agreement, Raymond James will be entitled to compensation at a commission rate of up to 2.0% of the gross sales price per share sold. In connection with the sale of our common stock on our behalf, Raymond James may be deemed to be an “underwriter” within the meaning of the Securities Act and the compensation of Raymond James may be deemed